CD63 and cancer: To further understand the phenotypic changes occurring upon cancer exosomes uptake in the two major cell type targeted by PDAC CD63+ Exos, we exposed an ex-vivo-established CAFs cell line and an endothelial cell line (bEnd.3) to cancer exosomes.